September 2019

Our September 2019 issue includes partnering companies focused on immuno-oncology, and antibodies among others, showcasing their developments. 

The editorial features cover the ongoing success of monoclonal antibodies, the search for immuno-oncology checkpoint inhibitor partners and how to negotiate a biopharma term sheet.  

We also launch the first of our BioPharma Thought Leader articles, in which we hear from the CEO of Lonza.